These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36599206)

  • 1. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
    Ekhlasi M; Sheikhi S; Majd ZK; Peiravian F; Yousefi N
    Value Health Reg Issues; 2023 Mar; 34():78-85. PubMed ID: 36599206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].
    Moiseeva OM; Rudakova AV
    Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.
    Nosrati M; Shahmirzadi NA; Afzali M; Zaboli P; Rouhani H; Hamedifar H; Hajimiri M
    J Family Med Prim Care; 2020 Jul; 9(7):3634-3638. PubMed ID: 33102342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension.
    Buendia JA; Patino DG; Lindarte EF
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):967-973. PubMed ID: 37403496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension.
    Dong W; Zhang Z; Chu M; Gu P; Hu M; Liu L; Huang J; Zhang R
    Front Pharmacol; 2023; 14():1122866. PubMed ID: 37637431
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.
    Safdar Z; Thakur A; Frost A
    South Med J; 2017 Mar; 110(3):223-228. PubMed ID: 28257550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
    Chen T; Chen J; Chen C; Zheng H; Chen Y; Liu M; Zheng B
    Pediatr Pulmonol; 2021 Jul; 56(7):2250-2258. PubMed ID: 33856119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
    Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
    Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
    Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
    Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).
    Aldalaan AM; Saleemi SA; Weheba I; Abdelsayed A; Aleid MM; Alzubi F; Zaytoun H; Alharbi N
    Pulm Circ; 2022 Apr; 12(2):e12083. PubMed ID: 35514768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.
    Coyle K; Coyle D; Blouin J; Lee K; Jabr MF; Tran K; Mielniczuk L; Swiston J; Innes M
    Pharmacoeconomics; 2016 May; 34(5):509-20. PubMed ID: 26739957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.
    Omura J; Makanji Y; Tanabe N; Yu DY; Tan JY; Lim S; Kouhkamari MH; Casorso J; Wu DB; Bloomfield P
    Pulm Ther; 2023 Dec; 9(4):511-526. PubMed ID: 37991630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.